Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse
Key facts
- Who runs it
- Sint Maartenskliniek
- Where
- Netherlands9 sites in 1 countryChoose a country to see its sites
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 174 people, planned
- Started
- 9 Feb 2023
- Expected to end
- Jan 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Rituximab
- Placebo
- Record updated
- 4 February 2026
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Polymyalgia rheumatica (PMR) diagnosis fulfilling the 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria
- Experiencing a PMR relapse, defined as recurring of symptoms and increase in erythrocyte sedimentation rate (ESR)/ C reactive protein (CRP)
- Unable to reduce glucocorticoid dose below 5mg/day prednisolone or equivalent
- Informed consent
Who cannot take part
- Treatment with systemic immunosuppressants (other than GC, MTX, leflunomide and azathioprine) 3 months prior to inclusion
- (clinical) suspect concomitant giant cell arteritis or other rheumatic inflammatory diseases
- concomitant conditions that might significantly interfere with PMR pain or movement evaluation as judged by the investigator
- previous hypersensitivity for RTX or contra-indications to RTX
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Polymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing treatment. A proof of concept study on Rituximab (RTX) vs placebo showed efficacy in 48 vs 21%(p=0.049) in glucocorticoid free remission after 21 weeks (Marsman et al. 2021). Though promising, the short study duration, small sample size and only few relapsing patients included in this study require further confirmation. Therefore a larger randomised controlled trial with longer follow up will be performed on RTX efficacy on glucocorticoid free remission in relapsing PMR patients during glucocorticoid taper.
The 2 groups in the trial
- RituximabTreatment being tested
1000mg rituximab intravenously once
- PlaceboPlacebo, for comparison
0mg rituximab (placebo) intravenously once
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Publications
- Polymyalgia rheumatica and giant cell arteritis: diagnosis and management.Current opinion in rheumatology, 2025
- Record updated
- 4 February 2026